Pantoprazole

Results: 55



#Item
41022020_Pantoprazole_Statistical_BPCA

022020_Pantoprazole_Statistical_BPCA

Add to Reading List

Source URL: www.fda.gov

Language: English
42Department of Health and Human Services - Drug Use Review

Department of Health and Human Services - Drug Use Review

Add to Reading List

Source URL: www.fda.gov

Language: English
43022020_Pantoprazole_Clinical_Addendum_ BPCA

022020_Pantoprazole_Clinical_Addendum_ BPCA

Add to Reading List

Source URL: www.fda.gov

Language: English
44Preliminary Data from a Pilot Study

Preliminary Data from a Pilot Study

Add to Reading List

Source URL: www.fda.gov

Language: English
45Department of Health and Human Services   Public Health Service Food and Drug Administration

Department of Health and Human Services Public Health Service Food and Drug Administration

Add to Reading List

Source URL: www.fda.gov

Language: English
46————————— CONTRAINDICATIONS ———————— Known hypersensitivity to any component of the formulation or to substituted benzimidazoles (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlight

————————— CONTRAINDICATIONS ———————— Known hypersensitivity to any component of the formulation or to substituted benzimidazoles (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlight

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-11-01 12:14:13
47State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 Williston VT[removed]http://dvha.vermont.gov

State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 Williston VT[removed]http://dvha.vermont.gov

Add to Reading List

Source URL: dvha.vermont.gov

Language: English - Date: 2013-05-21 21:10:49
48Proton Pump Inhibitors and Clopidogrel

Proton Pump Inhibitors and Clopidogrel

Add to Reading List

Source URL: www.health.gov.bc.ca

Language: English - Date: 2014-03-05 12:02:51
49––––––––––––––––––––CONTRAINDICATIONS–––––––––––––––––– Known hypersensitivity to any component of the formulation or to substituted benzimidazo

––––––––––––––––––––CONTRAINDICATIONS–––––––––––––––––– Known hypersensitivity to any component of the formulation or to substituted benzimidazo

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-12-17 14:08:21
50•  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROTONIX I.V. safely and effectively. See full prescribing information for PROTONIX I.V.

• HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROTONIX I.V. safely and effectively. See full prescribing information for PROTONIX I.V.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-12-17 14:07:43